Close
A list of our early phase haematology (Acute Leukaemia & MDS) trials which are open to recruitment at University College London Hospitals.
To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked IRAS Number, which will take you to the UCLH Find a Study database.
75276617ALE1002 - Menin ComboA Phase 1b Study of JNJ-75276617 in Combination with AML-Directed Therapies: A Phase 1b Study of JNJ-75276617 in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations | |
|---|---|
| IRAS Number: | 1005413 |
| Principal Investigator: | Dr Jenny O'Nions |
| Drug Class/ Treatrment: | JNJ-75276617 (Menin-KMT2A Inhibitor) |
| Patient Population: | Acute Myeloid Leukemia (AML) with KMT2A or NPM1 Alterations |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
EP0042-101A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate theSafety and Tolerability of EP0042 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies. | |
|---|---|
| IRAS Number: | 275864 |
| Principal Investigator: | Dr Jenny O'Nions |
| Drug Class/ Treatrment: | FLT3 inhibitor & Aurora Kinase Inhibitor: EP0042 Monotherapy and Combination - Oral administration |
| Patient Population: | Acute Myeloid Leukaemia (AML) or Myelodysplastic Syndromes (MDS) |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
PROMISEInvestigation into the combination of PLX2853 with Ruxolitinib in patients with intermediate-2 or high risk myelofibrosis not receiving an adequate response with ruxolitinib alone. | |
|---|---|
| IRAS Number: | 261523 |
| Principal Investigator: | Dr. Jenny O'Nion |
| Drug Class/ Treatrment: | PLX2853 (BET Inhibitor) + Ruxolitinib (JAK Inhibitor) |
| Patient Population: | Intermediate or High-Risk Myelofibrosis |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
88549968MPN1001A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms | |
|---|---|
| IRAS Number: | 1008190 |
| Principal Investigator: | Dr Jenny O'Nions |
| Drug Class/ Treatrment: | JNJ-88549968 (T-Cell Redirecting Bispecific Antbody) |
| Patient Population: | CALR-mutated Myeloproliferative Neoplasms (MPN)
|
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
CCS1477-02An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination with advanced haematological malignancies | |
|---|---|
| IRAS Number: | 259880 |
| Principal Investigator: | Dr Jenny O'Nions |
| Drug Class/ Treatrment: | CCS1477 (P300/CBP Inhibitor) |
| Patient Population: | Advanced Haematological Malignancies
|
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
FEDORAFEDORA : A phase II study to evaluate the tolerability, safety and activity of fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis | |
|---|---|
| IRAS Number: | 1003972 |
| Principal Investigator: | Dr Donal McLornan |
| Drug Class/ Treatrment: | Fedratanib (JAK2 Inhibitor) + Ropeginterferon Alfa-2b (Pegylated Interferon) |
| Patient Population: | Myelofibrosis |
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
ELECTRAA Phase 1b, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ELA026 in Adults and Adolescents with Secondary Hemophagocytic Lymphohistiocytosis (sHLH) | |
|---|---|
| Local Project Reference: | 145018 |
| Principal Investigator: | Dr Satyen Gohil |
| Drug Class/ Treatrment: | ELA026 (IgG1 SIRP-Directed Monoclonal Antibody) |
| Patient Population: | Secondary Hemophagocytic Lymphohistiocytosis (sHLH) Adults and Adolescents (≥12 years at the time of HLH diagnosis) |
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
KCAT19KCAT19: Allogeneic T cells expressing T cell receptor-KDEL and the chimeric antigen receptor CAT19 for the treatment of advanced CD19+ malignancies | |
|---|---|
| IRAS Number: | 1004920 |
| Principal Investigator: | Dr Maeve O’Reilly |
| Drug Class/ Treatrment: | CAR T-Cell Therapy |
| Patient Population: | Advanced CD19+ Malignancies |
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
